volasertib and 1-(5-((2-4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone

volasertib has been researched along with 1-(5-((2-4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone* in 1 studies

Other Studies

1 other study(ies) available for volasertib and 1-(5-((2-4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone

ArticleYear
Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.
    International journal of molecular sciences, 2020, Nov-16, Volume: 21, Issue:22

    USP7 is a promising target for the development of cancer treatments because of its high expression and the critical functions of its substrates in carcinogenesis of several different carcinomas. Here, we demonstrated the effectiveness of targeting USP7 in advanced malignant cells showing high levels of USP7, especially in taxane-resistant cancer. USP7 knockdown effectively induced cell death in several cancer cells of lung, prostate, and cervix. Depletion of USP7 induced multiple spindle pole formation in mitosis, and, consequently, resulted in mitotic catastrophe. When USP7 was blocked in the paclitaxel-resistant lung cancer NCI-H460

    Topics: A549 Cells; Cell Cycle Proteins; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Thiophenes; Ubiquitin-Specific Peptidase 7

2020